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Abstract Biological activities of BCR-ABL, an activated tyro- 
sine kinase oncogene responsible for pathogenesis of human leu- 
kemias, can be completely inactivated by a deletion of the BCR 
aminoterminal sequence with a tetramerizing property (BCR- 
ABL zll-40). We attempted several ways to restore the ability 
to induce growth factor independence to the de-oligomerized 
BCR-ABL /t l -40 and found that an additional deletion of the 
ABL SH3 domain could. In BCR-ABL/t l -40 reactivated by the 
SH3 deletion, transphosphoryation of other cellular proteins like 
p62 or SHC in vivo and autophosphorylation with recruitment of 
GRB-2 were also recovered. 
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I. Introduction 
BCR-ABL oncoproteins are found in Philadelphia chromo- 
some-positive chronic myelocytic (CML) or acute lymphocytic 
(ALL) human leukemias (reviewed in [1]). In vivo CML model 
utilizing retroviruses and studies on BCR-ABL transgenic mice 
have demonstrated that BCR-ABL causes leukemias. Transfor- 
mation of Ratl  fibroblasts and abolishment of growth factor 
dependence in, for example, interleukin-3 (IL-3)-dependent Ba/ 
F3 cells are convenient ways to test the biological activities of 
BCR-ABL. Ratl transformation is inhibited in BCR-ABL with 
various mutations including (a) 177 Y (tyrosine) to F (phenyla- 
lanine) which abolishes GRB-2 binding [2], (b) 1294 Y to F 
(major autophosphorylation site) [3], (c) SH2 domain mutation 
[4], and (d) a deletion of aminoterminal 40amino acids (BCR- 
ABL AIM0) which destroys the BCR tetramer domain [1,5 7] 
and so forth. However, while the 177F and 1294F mutations 
still retain their ability to abrogate growth factor dependence, 
the BCR-ABL A I~0 mutation does not. In order to examine 
how tetramerization can help activate ABL, we attempted to 
reactivate the ability of BCR-ABL A I~0 to induce growth 
factor independence by the following modifications. 
First, we coexpressed BCR-ABL A I~0 with MYC, because 
BCR-ABL not only cooperates with MYC but also dominant 
negative MYC expressions inhibit biological activities of BCR- 
ABL [8,9]. Furthermore, it has recently been shown that MYC 
expression can compliment the SH2 domain mutation of BCR- 
ABL [4]. Second, we made additional deletion mutations to 
BCR-ABL A I~0.  The c-ABL protein can be activated by dele- 
tions of either the SH3 domain (3SH3) [10-12] or a part of the 
last exon-encoded sequence (for example, APvuII) [13]. Third, 
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a myristoylation signal was added to BCR-ABL A1-40. Both 
SOS and FES have been shown to be activated by membrane 
routing by an addition of a myristoylation signal [14,15]. 
Among these strategies, only the SH3 deletion restored the 
ability to induce growth factor independence to BCR-ABL 
A1-40. 
2. Materials and methods 
P185 BCR-ABL ASH3 was constructed by excision of Bg/II-to- 
HinclI fragment followed by an in-frame fusion and the PvuII deletion 
was made as described [13]. The first 41 amino acids from v-ABL 
(Pstl-to-PstI fragment) [10] that contain a myristoylation signal were 
added to aminoterminus of P185 BCR-ABL AI~0 [6]. To simultane- 
ously express both P185 BCR-ABL AI~0 and MYC, a modified ver- 
sion of a retrovirus expression vector pSRc~MSVtkneo was utilized [9]. 
Retroviruses were made by the COS cell coexpression method escribed 
[6]. Ba/F3 cells were cultured in RPMI/10% fetal calf serum supple- 
mented with 15% conditioned medium from actively growing WEHI 3B 
cells as a source of interleukin-3 (1L-3). The 96-wells assay to test the 
ability to induce IL-3 independence was performed as described 
[3,16,18]. Approximately 106 Ba/F3 cells were infected with retroviruses 
and were cultured in the presence of IL-3. At 3 days postinfection, cells 
were washed 3 x to remove IL-3 and were plated into 96-wells culture 
dishes at roughly 104 cells/well. After 2 weeks wells that showed an 
outgrowth of lL-3-independent cells were scored positive. Ratl trans- 
formation assay was performed as described [6,8]. lmmunoprecipita- 
tion and Western blot analysis of BCR-ABL or GRB-2 were performed 
as described [4]. Anti-GRB-2 antibody isa gift from Dr. T. Takenawa 
at University of Tokyo. 
3. Results and discussion 
BCR-ABL with a deletion of the tetramer domain (BCR- 
ABL A I~0)  can no longer induce growth factor independence 
[7]. Autophosphorylation a d transphosphorylation of other 
cellular proteins like GAP (GTPase activating protein)-associ- 
ated p62 or SHC are dramatically reduced in BCR-ABL A I~0 
[7]. In order to obtain a hint to investigate the significance of 
tetramerization in BCR-ABL, several additional modifications 
to P185 BCR-ABL zllM0 (Fig. 1) were made to reactivate the 
ability to induce growth factor independence. The modifica- 
tions include coexpression with MYC [4], deletion of the ABL 
SH3 domain [10-12], deletion of a part of the ABL last exon- 
encoded sequence (PvuII/PvuII deletion) [13], aminoterminal 
tagging with a sequence containing a myristoylation signal from 
v-ABL, and combinations of those (Fig. 1). Helper-free retro- 
viruses expressing those constructs were made according to the 
transient COS cell expression system described previously [6]. 
Interleukin-3 (IL-3)-dependent mouse Ba/F3 cells were in- 
fected with those retroviruses and 2 different types of assay 
were performed. First, infected cells were deprived of IL-3 72 h 
after infection and plated into 96-wells to grossly quantitate the 
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ability to induce growth factor independence. Second, the 
whole infected population of cells were cultured in the presence 
of both IL-3 and G418 at 2 mg/ml for 10 days and then cultures 
were further continued in the absence of IL-3 for up to 4 weeks. 
BCR-ABL constructs that showed completely no survival of 
cells in the second assay were scored negative ( - )  in Fig. 1. The 
SH3 deletion turned out to be the only modification that could 
restore growth factor independence to P185 BCR-ABL A I~0.  
BCR-ABL mutants with the SH3 deletion could cause growth 
factor independence with a similar efficiency as wild type BCR- 
ABL when judged by the 96-wells assay (Fig. 1). An an- 
tiphosphotyrosine Western blot analysis of the survived cells 
revealed that autophosphorylation as well as tyrosine phospho- 
rylation of other cellular proteins including SHC and p62, 
which are good indicators of BCR-ABL-mediated transforma- 
tions [6,17,18], were also recovered (Fig. 2B). The intensities of 
autophosphorylation relative to the protein amounts were 
roughly the same in all forms of BCR-ABL that could induce 
growth factor independence. The tyrosine 177 (Y177) is one of 
the autophosphorylation sites in BCR-ABL and is recruited 
with GRB-2, an SH2/SH3-containing adaptor protein, which 
links between BCR-ABL and RAS pathway [2,17-19]. An anti- 
GRB-2 Western blot analysis of anti-ABL immunoprecipitates 
showed that the GRB-2 proteins bind to the reactivated BCR- 
ABLs (Fig. 2C). 
In Ratl  transformation assay, BCR-ABL with the SH3 do- 
main deletion or PvulI/PvuII deletion was as transforming as 
wild type BCR-ABL. BCR-ABL A I~0 reactivated by the addi- 
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Fig. I. Deletion of the SH3 domain restores growth factor independ- 
ence to P185 BCR-ABL AI-40. Schematic representation f the mu- 
tated P185 BCR-ABLs (1-10). LX, SH3, SH2, MYR (8-10), and MYC 
(5) show sequences encoded by the ABL last exon, the SH3 and SH2 
domains, v-ABL sequences containing a myristoylation signal, coex- 
pressed M YC, respectively. Deletion of amino acids 140 in BCR-ABL 
(4-10), deletion of the PvulIlPvuII sequence (3, 7, 10), and deletion of 
the SH3 domain (2, 6, 9) are shown. Ability (+) and inability (-) to 
induce interleukin-3 (IL-3) independence in Ba/F3 cells and results of 
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Fig. 2. Deletion of the SH3 domain restores autophosphorylation as 
well as transphosphorylation t  P185 BCR-ABL AI40. (A,B) Anti- 
ABL (A) and antiphosphotyrosine (B) Western blot analyses of total 
cell lysates from Ba/F3 cells expressing indicated molecular constructs. 
Ba/F3 cells were infected with mock (1), P185 BCR-ABL wild type (2: 
WT), and P185 A140 (3: AI~0) retroviruses, selected by G418 for 
2 weeks in the presence of IL-3. Lanes 4 (zlSH3) (P185 with SH3 domain 
deletion), 5 (APv) (P185 with deletion of the PvuII/PvuIl sequence), 
6 (A40 ASH3) (P185 A140 with SH3 domain deletion), and 7 (Myr-A40 
ASH3) (P185 AI~0 with a myristoylation signal and SH3 domain 
deletion) show Ba/F3 cells that survived IL-3 deprivation. The tyrosine- 
phosphorylated P62 and SHC proteins are indicated by arrows. 
(C) Anti-ABL immunoprecipitates from Ba/F3 cells expressing mock 
(1), P185 (2), P185 AI~0 (3) in the presence of IL-3, and P185 AI~,0 
with SH3 domain deletion (6), P185 A1-40 with a myristoylation signal 
and SH3 domain deletion (7) in the absence of 1L-3 were subjected to 
an anti-GRB-2 Western blot analysis. 
cells and its expression level was 10-20% of that of wild type 
BCR-ABL. The number of Ratl  colonies in soft agar derived 
from this mutant was roughly 20% of that in wild type BCR- 
ABL. Therefore, we tentatively conclude that the deletion of 
the SH3 domain not only reactivates the ability of BCR-ABL 
A 1 40  to induce growth factor independence but also the poten- 
tial to transform Ratl  cells. 
Biological function of the SH3 domain is to mediate protein 
traffic [20,21]. In GRB-2, PLCy, and type IV ABL, the destruc- 
tion of the SH3 domain relocalizes the protein from membrane 
ruffle, actin cytoskeleton, and nucleus, respectively [22,23]. 
Type IV ABL relocalized from nucleus to cytoplasm by the 
deletion of the SH3 domain acquires increased tyrosine kinase 
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activity. BCR-ABL, however, is totally cytoplasmic and a 
BCR-ABL mutant with a deletion of the first 60 amino acids 
of BCR with a tetramerizing property has a decreased binding 
to actin cytoskeleton but is still in the cytoplasm. Since associ- 
ation of BCR-ABL with actin cytoskeleton is governed by 
carboxyterminal ABL sequences and not by either the SH3 
domain or kinase activity of the protein [5,24], the deletion of 
the SH3 domain in BCR-ABL A1-40 may not significantly alter 
its intracellular localization. 
Mutations in the SH3 domain has been reported to activate 
not only nuclear c-ABL but also cytoplasmic -SRC [25,26]. 
Discoveries of molecules uch as 3BP-1 [27] and Abi-2 [28] that 
bind to the ABL SH3 domain strongly suggest hat functions 
of ABL could be regulated by protein/protein interactions 
through the SH3 domain [20,21]. Although in vivo binding to 
ABL has not been detected in 3BP-1, it is interesting that this 
protein functions as a GAP (GTPase activating protein) for 
RAC family of small GTP-binding proteins [27]. RAC is essen- 
tial for RAS-mediated transformation of fibroblasts [29] and 
transforming forms of ABL elicit RAS signals [2,17-19]. Given 
the fact that GAP accelerates the conversion of GTP-bound 
active form of GTP-binding proteins to GDP-bound inactive 
form, the ABL protein might be always accompanied by a 
negative regulator for transformation. Presence of molecules 
that inhibit the catalytic function of ABL has been previously 
suggested [30]. The very recently discovered ABL SH3 domain- 
binding protein Abi-2 directly modulates the kinase activity as 
well as the transforming activity of c-ABL through dual SH3 
domain/proline-rich sequence interactions [28]. Although we 
cannot rule out the possibility that deletion of the SH3 domain 
re-oligomerizes BCR-ABL A I~0,  our current hypothesis is 
that BCR sequence-dependent tetramerization might somehow 
suppress the SH3 domain-mediated negative regulation of 
ABL. 
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